The stock of Cardiff Oncology Inc (CRDF) has gone up by 9.69% for the week, with a 2.93% rise in the past month and a 11.78% rise in the past quarter. The volatility ratio for the week is 8.08%, and the volatility levels for the past 30 days are 8.30% for CRDF. The simple moving average for the past 20 days is -0.23% for CRDF’s stock, with a 5.72% simple moving average for the past 200 days.
Is It Worth Investing in Cardiff Oncology Inc (NASDAQ: CRDF) Right Now?
The stock has a 36-month beta value of 1.51. Opinions on the stock are mixed, with 5 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CRDF is 60.75M, and at present, short sellers hold a 28.46% of that float. On July 02, 2025, the average trading volume of CRDF was 1.21M shares.
CRDF) stock’s latest price update
Cardiff Oncology Inc (NASDAQ: CRDF) has experienced a rise in its stock price by 11.43 compared to its previous closing price of 3.15. However, the company has seen a gain of 9.69% in its stock price over the last five trading days. seekingalpha.com reported 2025-06-27 that Cardiff Oncology’s recent trial data readout delay has unnerved the market, but I see this as a potential buying opportunity for speculative investors. Leadership change is not a major risk factor. The new CMO’s pedigree suggests confidence in the company’s prospects ahead of the catalyst. The delay could suggest an attempt to improve poor data, or an ability to add to already strong data by waiting for more patient second scans.
Analysts’ Opinion of CRDF
Many brokerage firms have already submitted their reports for CRDF stocks, with Jefferies repeating the rating for CRDF by listing it as a “Hold.” The predicted price for CRDF in the upcoming period, according to Jefferies is $3.50 based on the research report published on June 24, 2025 of the current year 2025.
Craig Hallum, on the other hand, stated in their research note that they expect to see CRDF reach a price target of $8. The rating they have provided for CRDF stocks is “Buy” according to the report published on September 06th, 2024.
CRDF Trading at 11.89% from the 50-Day Moving Average
After a stumble in the market that brought CRDF to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -37.76% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CRDF starting from Levine James E., who purchase 2,752 shares at the price of $5.42 back on Dec 17 ’24. After this action, Levine James E. now owns 65,316 shares of Cardiff Oncology Inc, valued at $14,905 using the latest closing price.
Levine James E., the Chief Financial Officer of Cardiff Oncology Inc, purchase 2,400 shares at $5.00 during a trade that took place back on Dec 18 ’24, which means that Levine James E. is holding 67,716 shares at $12,000 based on the most recent closing price.
Stock Fundamentals for CRDF
Current profitability levels for the company are sitting at:
- -108.77 for the present operating margin
- 0.58 for the gross margin
The net margin for Cardiff Oncology Inc stands at -102.0. The total capital return value is set at -0.73. Equity return is now at value -74.15, with -61.51 for asset returns.
Based on Cardiff Oncology Inc (CRDF), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -31.52.
Currently, EBITDA for the company is -48.25 million with net debt to EBITDA at 0.44. When we switch over and look at the enterprise to sales, we see a ratio of 440.01. The receivables turnover for the company is 1.18for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.22.
Conclusion
To sum up, Cardiff Oncology Inc (CRDF) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
